Adimab (United States)

Recent papers from Adimab (United States)

1. Abstract 5538: Pan-αβ-T-cell reactive anti-TCR VHH bispecifics demonstrate potent cytotoxicity through novel constant region targetingCancer Research · 2026
2. Abstract 435: Novel anti-CD3 heavy chain-only antibodies for use in T-cell engaging therapeutics.Cancer Research · 2026
3. Abstract A026: Discovery and development of a transferrin receptor antibody panel for efficient blood-brain barrier delivery as part of a multispecific antibodyCancer Research · 2026
4. Abstract C003: High-throughput discovery of rare anti-tumor TCRs via synthetic yeast-based librariesCancer Immunology Research · 2026
5. Abstract C001: Rapid and efficient generation of format-diverse co-stimulatory CD28 and CD3 multispecific antibody panels for T cell engagement via complementary technologiesCancer Immunology Research · 2026
6. Abstract C002: Novel anti-CD3 heavy chain-only antibodies for use in T-cell engaging therapeuticsCancer Immunology Research · 2026
7. Development of a humanized anti-fibrin monoclonal antibody for the treatment of neuroinflammatory and retinal diseasesJournal of Neuroinflammation · 2025
8. Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodiesScience Advances · 2025
9. Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodiesmAbs · 2025
10. Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies2024
11. Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflowsmAbs · 2024
12. Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38Cell Reports · 2024
13. Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2Pathogens and Immunity · 2024
14. Abstract 5792: Rapid and efficient generation of panels of T cell engaging (TCE) multispecific antibodies via complementary technologiesCancer Research · 2024
15. Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP382024
16. Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-22023
17. Characterization of SARS-CoV-2 Convalescent Patients’ Serological Repertoire Reveals High Prevalence of Iso–RBD Antibodies2023
18. Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing VariantsAntibodies · 2023
19. Defining and Studying B Cell Receptor and TCR InteractionsThe Journal of Immunology · 2023
20. Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibodyScience Translational Medicine · 2023